NCT02044055

Brief Summary

HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication. Nucleosides analogues have only a minor impact on quantitative HBs Ag level. Data about vertical HDV transmission are old, justifying a new study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 23, 2014

Completed
8 months until next milestone

Study Start

First participant enrolled

October 1, 2014

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2017

Completed
Last Updated

April 27, 2017

Status Verified

April 1, 2017

Enrollment Period

2.5 years

First QC Date

January 18, 2014

Last Update Submit

April 26, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Hepatitis D antibodies (Ab) in children

    Antibodies (Ab) against Hepatitis D Virus (HDV)

    up to 10 years (expected average: 5 years)

Secondary Outcomes (1)

  • HDV RNA in children with positive HDV Ab

    up to 10 years (expected average: 5 years)

Study Arms (1)

Children born to HBV-HDV women

Children born to HBV-HDV co-infected women will be checked for: * HDV antibodies * if positive, HDV RNA

Eligibility Criteria

Age9 Months - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

All children born in the Maternity Department, Lariboisiere Hospital, from HBV-HDV co-infected women

You may qualify if:

  • children born in the Maternity Department, Lariboisiere Hospital,
  • from HBV-HDV co-infected women
  • with a positive HDV RNA during pregnancy in the pregnant woman

You may not qualify if:

  • negative HDV RNA during pregnancy in the pregnant woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Lariboisiere

Paris, 75475, France

Location

Related Publications (1)

  • Sellier PO, Maylin S, Brichler S, Bercot B, Lopes A, Chopin D, Pogliaghi M, Munier AL, Delcey V, Simoneau G, Evans J, Gordien E, Simon F, Bergmann JF. Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int. 2018 Apr;38(4):611-618. doi: 10.1111/liv.13556. Epub 2017 Sep 12.

MeSH Terms

Conditions

Hepatitis D

Condition Hierarchy (Ancestors)

Hepatitis, Viral, HumanVirus DiseasesInfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System Diseases

Study Officials

  • Pierre O SELLIER, M.D., Ph.D

    Hopital Lariboisiere

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor at University Paris VII Denis Diderot, physician

Study Record Dates

First Submitted

January 18, 2014

First Posted

January 23, 2014

Study Start

October 1, 2014

Primary Completion

April 1, 2017

Study Completion

April 1, 2017

Last Updated

April 27, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will not share

Locations